Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction

Pulmonary Circulation

Volumn 2, Issue 2, 2012, Pages 163-169

  De Jesus Perez, Vinicio A ^a   Haddad, Francois ^a   Zamanian, Roham T ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Congestive heart failure; Echocardiography; Hemodynamics; Pulmonary hypertension; Therapeutics

Indexed keywords

EID: 84874677849     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.97598     Document Type: Review

References (51)

1. Oudiz RJ. Secondary Pulmonary Hypertension. Curr Treat Options Cardiovasc Med 2001;3:115-24.
2. Hoeper MM. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009;30:369-75.
3. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
4. Shammas RL, Khan NU, Nekkanti R, Movahed A. Diastolic heart failure and left ventricular diastolic dysfunction: What we know, and what we don’t know! Int J Cardiol 2007;115:284-92.
5. Garg R, Packer M, Pitt B, Yusuf S. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993;22:3A-5A.
6. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002;7:17-27.
7. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9.
8. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-50.
9. Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart 2006;92:1259-64.
10. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-32.
11. Sanders D, Dudley M, Groban L. Diastolic dysfunction, cardiovascular aging, and the anesthesiologist. Anesthesiol Clin 2009;27:497-517.
12. Sagie A, Benjamin EJ, Galderisi M, Larson MG, Evans JC, Fuller DL, et al. Reference values for Doppler indexes of left ventricular diastolic filling in the elderly. J Am Soc Echocardiogr 1993;6:570-6.
13. Scalia GM, Khoo SK, O’Neill S. Age-related changes in heart function by serial echocardiography in women aged 40-80 years. J Womens Health (Larchmt) 2010;19:1741-5.
14. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119-26.
15. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 2008;118:2190-9.
16. Grzybowski J, Bilinska ZT, Ruzyllo W, Kupść W, Michalak E, Szcześniewska D, et al. Determinants of prognosis in nonischemic dilated cardiomyopathy. J Card Fail 1996;2:77-85.
17. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004;43: 48S-55S.
18. Oudiz RJ. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007;28:233-41, x.
19. Rogers WB, Prisant LM, Houghton JL, Frank MJ. Congestive heart failure with normal ejection fraction. A different mechanism requiring different therapy. Postgrad Med 1992;91:207-14.
20. Moller JE, Hillis GS, Oh JK, Pellikka PA. Prognostic importance of secondary pulmonary hypertension after acute myocardial infarction. Am J Cardiol 2005;96:199-203.
21. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004;350:1953-9.
22. Desai A. Current understanding of heart failure with preserved ejection fraction. Curr Opin Cardiol 2007;22:578-85.
23. Haney S, Sur D, Xu Z. Diastolic heart failure: a review and primary care perspective. J Am Board Fam Pract 2005;18:189-98.
24. Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54:S85-96.
25. How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J 1998;19:990-1003.
26. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left v entricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002;90:1284-9.
27. Picard MH, Popp RL, Weyman AE. Assessment of left ventricular function by echocardiography: a technique in evolution. J Am Soc Echocardiogr 2008;21:14-21.
28. Ritchie RH, Rosenkranz AC, Kaye DM. B-type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target. Curr Mol Med 2009;9:814-25.
29. Mohammed AA, Januzzi JL Jr. Natriuretic peptides in the diagnosis and management of acute heart failure. Heart Fail Clin 2009;5:489-500.
30. Januzzi JL, Bayes-Genis A. Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure. Drug News Perspect 2009;22:267-73.
31. Mohammed AA, Januzzi JL Jr. Natriuretic peptide guided heart failure management. Curr Clin Pharmacol 2009;4:87-94.
32. van Kimmenade RR, Januzzi JL Jr. The evolution of the natriuretic peptides-Current applications in human and animal medicine. J Vet Cardiol 2009;11 Suppl 1:S9-21.
33. Lukowicz TV, Fischer M, Hense HW, Döring A, Stritzke J, Riegger G, et al. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. Eur J Heart Fail 2005;7:525-31.
34. Saul L, Shatzer M. B-type natriuretic peptide testing for detection of heart failure. Crit Care Nurs Q 2003;26:35-9.
35. Mottram PM, Haluska BA, Marwick TH. Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic heart failure: Correlation with cardiac function, hemodynamics, and workload. Am Heart J 2004;148:365-70.
36. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003;92:1434-8.
37. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010;56:845-54.
38. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588-95.
39. Lam CS, Grewal J, Borlaug BA, Ommen SR, Kane GC, McCully RB, et al. Size, shape, and stamina: The impact of left ventricular geometry on exercise capacity. Hypertension 2010;55:1143-9.
40. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992;19:48-54.
41. Nootens M, Wolfkiel CJ, Chomka EV, Rich S. Understanding right and left ventricular systolic function and interactions at rest and with exercise in primary pulmonary hypertension. Am J Cardiol 1995;75:374-7.
42. Costanzo MR, Augustine S, Bourge R, Bristow M, O’Connell JB, Driscoll D, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995;92:3593-612.
43. Grady KL, Jalowiec A, White-Williams C, Pifarre R, Kirklin JK, Bourge RC, et al. Predictors of quality of life in patients with advanced heart failure awaiting transplantation. J Heart Lung Transplant 1995;14:2-10.
44. Braun S, Schrotter H, Schmeisser A, Strasser RH. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int J Cardiol 2007;115:67-72.
45. Virgolini I, Kaliman J, Fitscha P, O’Grady J, Rogatti W, Sinzinger H. Beneficial effect of long-term PGE1-treatment in left ventricular heart failure. Prostaglandins Leukot Essent Fatty Acids 1989;38:177-80.
46. Auinger C, Virgolini I, Weissel M, Bergmann H, Sinzinger H. Prostacyclin I2 (PGI2) increases left ventricular ejection fraction (LVEF). Prostaglandins Leukot Essent Fatty Acids 1989;36:149-54.
47. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
48. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin-A Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347-54.
49. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: A double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103.
50. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004;44:2339-48.
51. Guazzi M, Tumminello G, Di Marco F, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther 2004;76:371-8.